Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 07, 2024 07:00 ET
|
Mural Oncology, Inc.
WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024 16:15 ET
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
September 26, 2024 07:00 ET
|
Mural Oncology, Inc.
Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal...
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
September 23, 2024 07:00 ET
|
Mural Oncology, Inc.
WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
September 10, 2024 07:00 ET
|
Mural Oncology, Inc.
Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024 16:30 ET
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology to Present at Two Upcoming Investor Conferences
August 27, 2024 07:00 ET
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
August 13, 2024 07:15 ET
|
Mural Oncology, Inc.
Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025 On...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024 16:15 ET
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
July 31, 2024 07:00 ET
|
Mural Oncology, Inc.
WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...